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Volume 57, Number 5S Abstracts 63Srates were 82 and 95% (P < .05). Results of AVS altered
localization of disease compared with what had been antic-
ipated based on preoperative imaging, and thus inﬂuenced
surgical decision making in 23 (43%) of cases. There were
no false positives based on surgical resection.
Conclusions: AVS is an important procedure in the
work up of hyperaldosteronism to help identify and localize
metabolically active tumors. It is an additional area in medi-
cine where a vascular surgeon can lend expertise. Success
with the procedure improves with experience and should
be done by high volume surgeons.
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Comparative Effect of Carvedilol Versus Bisoprolol in
Patients Undergoing Femoropopliteal Stenting
Yoshimitsu Soga1, Osamu Iida2. 1Cardiology, Kokura
Memorial Hospital, Kitakyushu, Japan; 2Kansai Rosai
Hospital, Amagasaki, Japan
Objectives: To compared the effects of beta-blokers in
patient undergoing femoropopliteal stenting.
Methods: This study was a multicenter retrospective
registry of prospectively maintained database. Between
January 2004 and December 2011, 438 patients (532
limbs) who treated by carvedilol (187 patients, 229 limbs)
or bisoprolol (251 patients, 303 limbs) were identiﬁed and
analyzed. The endpoints of this study were primary andFig. Primary patency after femoropopliteal stenting in patients
with bisoprolol and with carvedilol.secondary patency, overall survival and freedom from major
adverse limb events (MALE; includes any repeat revascular-
ization and major amputation). The mean follow-up period
was 27+/17 months.
Results: Primary patency was signiﬁcantly higher in the
bisoprolol-treated group than in the carvedilol-treated
group (71.7% vs 55.9% at 3-year; P ¼ .0006). Secondary
patency and freedom from MALE were also signiﬁcantly
higher in the bisoprolol-treated group (92.7% vs 76.1% at
3-year; P ¼ .0004 and 75.2% vs 58.0% at 3-year; P <
.0001, respectively). However, overall survival was similar
between both groups (82.0% vs 82.6% at 3-year; P ¼ .44).
After correcting with baseline variables, bisoprolol was found
to be effective for primary patency (Hazard ratio 0.56, 95%
conﬁdential interval 0.37 to 0.83, adjusted P ¼ .005).
Conclusions: In the vessel patency and the incidence
of MALE after femoropopliteal stenting, patients in
whom bisoprolol was given experienced better than those
in whom carvedilol was given.
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Comparison of Outcomes Between Bare Metal and
Covered Nitinol Stents in the Treatment of TASC C
and D Superﬁcial Femoral Artery (SFA) and Popliteal
Lesions
Jesus Matos2, Carlos F. Bechara1, Neal R. Barshes1, Briauna
Lowery1, George Pisimisis1, Sherene Sharath1, Peter H. Lin2,
Panos Kougias1. 1Surgery, Michael E. DeBakey VAMC,
Houston, Tex; 2Baylor College of Medicine, Houston, Tex
Objectives: We sought to determine the relative effec-
tiveness of bare metal (BM) and covered stents (CS) when
used in the treatment of patients with long TASC-II D SFA
and popliteal lesions.
Methods: This was a retrospective cohort analysis of
consecutive patients with SFA and popliteal TASC II
type C and D lesions, who underwent endovascular inter-
vention for claudication or critical limb ischemia with either
BM or CS. Cox regression was used for time to event anal-
ysis and logistic regression for analysis of categorical
outcomes. All results are reported adjusted for statistically
signiﬁcant covariates.
Results: We studied 166 patients for an average of 18
(range, 3-42) months. Treated lesions had an average
length of 32 cm (range, 15-52 cm) and included total
occlusions (n ¼ 91) and mixed stenoses and occlusions
(n ¼ 75). Covered stents were more commonly placed
for total occlusions (71% vs 44%; P ¼ .001). The BM stents
were more commonly placed in patients on statins (79% vs
60%; P ¼ .014). Otherwise the two groups were similar
in age, Rutherford stage on initial presentation, runoff
status, and comorbidity distribution. The primary patency
for the CS vs the BM group was 61% vs 43%, 42% vs
27%, and 34% vs 20% at 12, 18, and 24 months respectively
(P ¼ .03). Secondary patency for the CS vs the BM group
was 76% vs 73%, 62% vs 65%, and 56% vs 65% at 12, 18,
and 24 months respectively (P ¼ .65). Major amputations
(HR, 1.85; P ¼ .4), open reinterventions (HR, 1.43; P ¼
.34) and endovascular reinterventions (HR, 1.41; P ¼ .43)
were similar between the groups. Patients with claudication
